One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis.
For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.
Acpru /Id# 271617, Grayslake, Illinois, United States
Celerion (Site 0001), Lincoln, Nebraska, United States
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Hunan Cancer Hospital, Changsha, Hunan, China
Research Centers of America ( Hollywood ), Hollywood, Florida, United States
Research Centers of America, Hollywood, Florida, United States
Acpru /Id# 270532, Grayslake, Illinois, United States
Dallas Clinical Research Unit, Dallas, Texas, United States
Labcorp Clinical Research Unit Inc. (Site 0001), Honolulu, Hawaii, United States
Celerion, Tempe, Arizona, United States
PPD Austin Research Unit, Austin, Texas, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.